Insider trade

Stryker Corporation (SYK): Director sold ~$4.84M

Ronda E Stryker, Director at Stryker Corporation, sold ~$4.84M of Stryker Corporation shares.

~$4.84M
Approx. value · 12K sh @ $396.69
3.61M
Holds after · shares reported
Traded
Jan 31, 2025
Filed
Feb 5, 2025

What stands out in this filing

  • The sale was 0.3% of the shares this insider held before it; the filing reports 3,607,467 shares, held indirectly afterwards.
  • 12,213 shares at an average of $396.69 each, as reported on the form.
  • No footnote on the form refers to a pre-arranged trading plan (Rule 10b5-1).

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Feb 2, 2023InsiderOfficer sold ~$211K of SYK shares in the open market
  2. Jan 15, 2025Congress · 1 personMembers of Congress: 2 purchases
  3. Jan 31, 2025 · this disclosureInsiderDirector sold ~$4.84M of SYK shares in the open market

What came next

  1. Jan 31, 2025Insider · 1 personInsiders: 6 sales (~$87.8M)
  2. Feb 18, 2025InsiderDirector sold ~$942K of SYK shares in the open market
  3. Feb 26, 2025CongressDisclosed partial sale of SYK — reported range $15,001 - $50,000
  4. Feb 28, 2025FDARecall: Monterey AL Implant Inserter; 14/16mm; Catalog 48019120.
  5. Feb 28, 2025FDARecall: Monterey AL Implant Inserter; 10/12mm; Catalog 48019100.
  6. Mar 11, 2025FDAFDA device clearance: iBur 3.0mm Diamond Match Head, Distal Bend (8431-107-030D); iBur 3.0mm Precision Round, Distal Bend (8431-009-030); iBur 4.0mm Precision Round, Distal Bend (84…
  7. Mar 13, 2025CongressDisclosed partial sale of SYK — reported range $50,001 - $100,000
  8. Mar 21, 2025FDAFDA device clearance: Excelsior XT-27 Microcatheter, Excelsior XT-27 Flex Microcatheter, Excelsior XT-27 Pre-Shaped Microcatheter, Excelsior XT-27 Flex Pre-Shaped Microcatheter
  9. Mar 21, 2025FDAFDA device clearance: Consolidated Operating Room Equipment (CORE) 2 Console
  10. Mar 24, 2025FDAFDA device clearance: Sonopet iQ Ultrasonic Aspirator System (5500-050-000)
  11. Mar 28, 2025FDARecall: Guide Wire with Ruler Tube 3x800 mm DIA; Catalog number/REF: 2351-3080S;
  12. Mar 28, 2025FDARecall: Guide Wire with Ruler Tube 3x1000 mm DIA; Catalog number/REF: 2351-3100S;
  13. Apr 7, 2025Congress · 2 peopleMembers of Congress: 1 purchase, 1 sale
  14. Apr 8, 2025Congress · 1 personMembers of Congress: 2 sales
  15. Apr 15, 2025FDAFDA device clearance: OptaBlate Radiofrequency (RF) Generator System
  16. Apr 17, 2025CongressDisclosed purchase of SYK — reported range $15,001 - $50,000
  17. May 6, 2025Insider · 1 personInsiders: 6 sales (~$75.4M)
  18. May 12, 2025InsiderOfficer sold ~$482K of SYK shares in the open market
  19. May 15, 2025FDAFDA device clearance: OptaBlate BVN Intraosseous Nerve Ablation System (10mm Probe Single Kit); OptaBlate BVN Intraosseous Nerve Ablation System (10mm Probe Dual Kit)
  20. May 21, 2025FDAFDA device clearance: Stryker AlphaVent™ Knotless SP Biocomposite Anchor
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Stryker Corporation

For Stryker Corporation, OQRO holds 13 insider filings (SEC Form 4 or Form 144), 2 Congress trade reports and 2 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its SYK page.

Other recent filings by Ronda E Stryker, Director

The full history of Ronda E Stryker, Director is on the profile page.

How this filing works

Explore the data

Common questions

Which Stryker Corporation (SYK) insider traded, and how much?

Ronda E Stryker, Director at Stryker Corporation, sold ~$4.84M of Stryker Corporation shares. 12K shares at $396.69.

When did it happen, and when was it made public?

Traded: Jan 31, 2025. Filed: Feb 5, 2025. That is 5 days between the two dates.

What stands out in this filing?

The sale was 0.3% of the shares this insider held before it; the filing reports 3,607,467 shares, held indirectly afterwards. 12,213 shares at an average of $396.69 each, as reported on the form. No footnote on the form refers to a pre-arranged trading plan (Rule 10b5-1).

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Stryker Corporation recently?

For Stryker Corporation, OQRO holds 13 insider filings (SEC Form 4 or Form 144), 2 Congress trade reports and 2 federal contract awards dated in the last 90 days. They are listed on the SYK page.

Does this mean SYK stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Stryker Corporation

Everything OQRO holds on this company is on its SYK page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data